The quarter also saw Dr Reddy’s introduce in India its first digital therapeutic, Nerivio, an FDA-cleared smartphone-controlled prescribed wearable device for acute treatment of migraine.

Dr Reddy's CEO, branded markets (India and emerging markets), M V Ramana maintined that considering the number of migraine patients in India today especially the acute and the chronic ones who have a large number of episodes per month, “this is a good solution”.

“At least the initial set of customers that have used[Nerivio], there is traction. But of course, this is just the initial ones, we have to see how a large set of the neurologists would look at this product and how they would recommend it,” Ramana told Scrip.

The company is also working on plans to support patients who might need financial help to access to the product in India, largely an out-of-pocket market.

“So we're working on it, but I think there are a good number of patients or consumers who have the ability to buy a product like this,” the executive added.

Dr Reddy’s had earlier this year entered into license and supply agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, for the exclusive marketing and distribution of Nerivio in India.

While the agreement is focused on India, the companies at the time said that they expect to continue discussions about expanding to additional territories outside the US and China.

Dr Reddy's Looking For “Bigger Than Usual” Deals But Not In A Rush

Strikes deal with Hengrui for pyrotinib

More from Business

More from Scrip